Abstract
Treatment with thyroid hormone is needed in patients with differentiated thyroid carcinoma (DTC) after the initial treatment (thyroidectomy followed, in most cases, by radioiodine remnant ablation) for two reasons: a) Correction of hypothyroidism in an athyreotic patient (replacement therapy); b) Blockade of thyrotropin (TSH) secretion in view of the TSH-dependence of DTC (TSH-suppressive therapy). Levothyroxine (L-T4) is the hormone of choice, since combination with levotriiodothyronine does not add any clear advantage with respect to L-T4 monotherapy. While replacement therapy obviously is a lifelong requirement, duration of TSH-suppressive therapy depends on the tumor risk stratification after and the response to the initial treatment. According to recent European and American guidelines, in low-risk DTC LT4 treatment should be carried out at TSH-suppressive doses until there is evidence that the patient is disease-free. In high-risk DTC, TSH suppression should be maintained for several years after such an evidence has been achieved. Afterwards, the patient can be shifted to replacement doses, also to avoid the risks of iatrogenic thyrotoxicosis, especially in the elderly and/or in the presence of cardiovascular disease. The dose of L-T4 must be invidualized; particular attention must be given to the coexistence of pathophysiological conditions or drug treatments that may affect L-T4 absorption or metabolism.
Keywords: Differentiated thyroid carcinoma, L-thyroxine, Thyrotropin, Thyrotropin suppression, Free thyroxine
Current Cancer Therapy Reviews
Title: Thyroid Hormone Treatment for Differentiated Thyroid Carcinoma: What Drug, How Long, What Dose?
Volume: 5 Issue: 4
Author(s): Eliana Piantanida, Emanuele Compri, Myriam Gandolfo, Lorenza Sassi, Gianlorenzo Dionigi, Adriana Lai, Maria Laura Tanda and Luigi Bartalena
Affiliation:
Keywords: Differentiated thyroid carcinoma, L-thyroxine, Thyrotropin, Thyrotropin suppression, Free thyroxine
Abstract: Treatment with thyroid hormone is needed in patients with differentiated thyroid carcinoma (DTC) after the initial treatment (thyroidectomy followed, in most cases, by radioiodine remnant ablation) for two reasons: a) Correction of hypothyroidism in an athyreotic patient (replacement therapy); b) Blockade of thyrotropin (TSH) secretion in view of the TSH-dependence of DTC (TSH-suppressive therapy). Levothyroxine (L-T4) is the hormone of choice, since combination with levotriiodothyronine does not add any clear advantage with respect to L-T4 monotherapy. While replacement therapy obviously is a lifelong requirement, duration of TSH-suppressive therapy depends on the tumor risk stratification after and the response to the initial treatment. According to recent European and American guidelines, in low-risk DTC LT4 treatment should be carried out at TSH-suppressive doses until there is evidence that the patient is disease-free. In high-risk DTC, TSH suppression should be maintained for several years after such an evidence has been achieved. Afterwards, the patient can be shifted to replacement doses, also to avoid the risks of iatrogenic thyrotoxicosis, especially in the elderly and/or in the presence of cardiovascular disease. The dose of L-T4 must be invidualized; particular attention must be given to the coexistence of pathophysiological conditions or drug treatments that may affect L-T4 absorption or metabolism.
Export Options
About this article
Cite this article as:
Piantanida Eliana, Compri Emanuele, Gandolfo Myriam, Sassi Lorenza, Dionigi Gianlorenzo, Lai Adriana, Tanda Laura Maria and Bartalena Luigi, Thyroid Hormone Treatment for Differentiated Thyroid Carcinoma: What Drug, How Long, What Dose?, Current Cancer Therapy Reviews 2009; 5 (4) . https://dx.doi.org/10.2174/157339409789712717
DOI https://dx.doi.org/10.2174/157339409789712717 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuroinflamm-Aging and Neurodegenerative Diseases: An Overview
CNS & Neurological Disorders - Drug Targets From Pituitary Adenoma to Pituitary Neuroendocrine Tumors: How Molecular Pathways may Impact the Therapeutic Management?
Endocrine, Metabolic & Immune Disorders - Drug Targets Autophagy as a Molecular Target of Flavonoids Underlying their Protective Effects in Human Disease
Current Medicinal Chemistry Cannabinoids and Cardiovascular Disease: The Outlook for Clinical Treatments
Current Vascular Pharmacology Resveratrol, a Phytochemical Inducer of Multiple Cell Death Pathways: Apoptosis, Autophagy and Mitotic Catastrophe
Current Medicinal Chemistry Parathyroid Hormone Determination in Ultrasound-Guided Fine Needle Aspirates Allows the Differentiation between Thyroid and Parathyroid Lesions: Our Experience and Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Liver X Receptor: Crosstalk Node for the Signaling of Lipid Metabolism,Carbohydrate Metabolism, and Innate Immunity
Current Signal Transduction Therapy HDL Genetic Defects
Current Pharmaceutical Design Isoflavones and Bone Health
Current Women`s Health Reviews The Effect of GLUT1 on the Survival Rate and Immune Cell Infiltration of Lung Adenocarcinoma and Squamous Cell Carcinoma: A Meta and Bioinformatics Analysis
Anti-Cancer Agents in Medicinal Chemistry Drosophila Renal Organ as a Model for Identification of Targets and Screening of Potential Therapeutic Agents for Diabetic Nephropathy
Current Drug Targets Cytochrome P450s: Mechanisms and Biological Implications in Drug Metabolism and its Interaction with Oxidative Stress
Current Drug Metabolism Poly (D,L-lactic-co-glycolide) Nanoparticles for the Improved Therapeutic Efficacy of All-trans-retinoic Acid: A Study of Acute Myeloid Leukemia (AML) Cell Differentiation In Vitro
Medicinal Chemistry Quinoline as a Privileged Scaffold in Cancer Drug Discovery
Current Medicinal Chemistry Application of Recombinant and Non-Recombinant Peptides in the Determination of Tumor Response to Cancer Therapy
Current Pharmaceutical Biotechnology High CXCR4 Expression Correlates with Sunitinib Poor Response in Metastatic Renal Cancer
Current Cancer Drug Targets GEMSP: A New Therapeutic Approach to Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry TMSCl-NaI-MeCN Reagent Mediated Simple Two-Step Synthesis of Phenolic Benzosultams
Letters in Organic Chemistry Olive Oil and Cancer Risk: an Update of Epidemiological Findings through 2010
Current Pharmaceutical Design Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges
Current Vascular Pharmacology